Abstract 330P
Background
After radiotherapy (RT) to the left breast, the long-term risk of developing various cardiovascular diseases may increase. In our study, we present how deep inspiration treatment changes the doses of organs at risk (OAR), especially the heart. Furthermore, we examined if there is a relationship between the size of the irradiated target area and the dose on the heart.
Methods
From May 2016 to August 2020, 503 patients with left-sided breast cancer underwent RT at our institute. Since May 2018, we have treated our patients in deep breathing (DIBH) using the “voluntary breath-hold” technique. We compared the Dmean and Dmax values for the most critical OAR (left lung, heart, left ventricle, LAD-left anterior descending artery) based on the two treatment methodologies. Subsequently, both groups were then further subdivided into whether the treatment was given by standard fractionation or hypofractionation and created 3-3 groups based on the size of the target area (PTV).
Results
In patients treated with normal fractionation in DIBH vs. without, the doses of the OARs were the following: lung Dmean: 9.3 Gy vs. 9.96 Gy (p=0.029), left ventricle Dmean: 3.52 Gy vs. 7.56 Gy (p=2.69E-27), heart Dmean: 2.78 vs. 5.31 (p=1.11E-24), LAD Dmean 12.17 vs. 25.91 Gy (p=4.63E-24) respectively. In the hypofractionated group with vs. without DIBH the values were lung Dmean: 7.43 Gy vs. 8.08 Gy (p=0.17), left ventricle Dmean: 3.48 Gy vs 6.4 Gy (p=2.64E-10), heart Dmean: 2.64 vs 4.62 (p=2.96E-08), LAD Dmean 11.46 vs 18.35 Gy (p=3.37E-06) respectively. In the standard fractionated group, the average doses for each structure decreased mostly in women with large breast sizes after DIBH treatment. Generally, as the breast size increases, the values of the left ventricle, heart, and LAD increase, whilst the values of the lungs decrease. Although, a significant difference could only be detected in a few categories.
Conclusions
DIBH RT of the left breast significantly reduces radiation exposure to crucial OAR than free-breathing radiation therapy. At the same time, the coverage of the target area does not change, and our results suggest that this benefit is most pronounced in patients with large breast sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
233P - Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Presenter: Marianela Bringas Beranek
Session: Poster session 02
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02
236TiP - Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Presenter: Shingo Kitagawa
Session: Poster session 02
247P - KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
Presenter: Linxiaoxi Ma
Session: Poster session 02
248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Presenter: Francesca Ligorio
Session: Poster session 02
250P - The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer
Presenter: Luke Steventon
Session: Poster session 02
251P - Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Presenter: Jose Angel García-Sáenz
Session: Poster session 02